Drug intelligence / Profile preview

APX-New1

Development stage: Preclinical
Lead developer: Aptabio Therapeutics
Modality: Small Molecules

Overview

APX-New1 is a small molecule inhibitor developed by Aptabio Therapeutics that targets the NADPH oxidase (NOX) enzyme family. It is currently being developed for the treatment of Parkinson's disease. The drug's mechanism involves the inhibition of NOX enzymes, which are key producers of reactive oxygen species (ROS) in the central nervous system. By reducing oxidative stress and subsequent neuroinflammation, APX-New1 aims to provide neuroprotective effects and slow the progression of neurodegeneration in patients with Parkinson's disease.

Targets

NOX4 (NADPH oxidase 4)

Beyond the preview

Go deeper on APX-New1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APX-New1.

Explore the full profile